Tracy R Daniels
Overview
Explore the profile of Tracy R Daniels including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1072
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daniels T, Martinez-Maza O, Penichet M
Cancer Immunol Immunother
. 2011 Dec;
61(9):1535-46.
PMID: 22193986
Although most monoclonal antibodies developed for cancer therapy are of the IgG class, antibodies of the IgE class have certain properties that make them attractive as cancer therapeutics. These properties...
2.
Daniels T, Leuchter R, Quintero R, Helguera G, Rodriguez J, Martinez-Maza O, et al.
Cancer Immunol Immunother
. 2011 Dec;
61(7):991-1003.
PMID: 22127364
Breast and ovarian cancer are two of the leading causes of cancer deaths among women in the United States. Overexpression of the HER2/neu oncoprotein has been reported in patients affected...
3.
Rodriguez J, Luria-Perez R, Lopez-Valdes H, Casero D, Daniels T, Patel S, et al.
Leuk Lymphoma
. 2011 Aug;
52(11):2169-78.
PMID: 21870996
A number of antibodies have been developed that induce lethal iron deprivation (LID) by targeting the transferrin receptor 1 (TfR1/CD71) and either neutralizing transferrin (Tf) binding, blocking internalization of the...
4.
Daniels T, Bernabeu E, Rodriguez J, Patel S, Kozman M, Chiappetta D, et al.
Biochim Biophys Acta
. 2011 Aug;
1820(3):291-317.
PMID: 21851850
Background: Traditional cancer therapy can be successful in destroying tumors, but can also cause dangerous side effects. Therefore, many targeted therapies are in development. The transferrin receptor (TfR) functions in...
5.
Daniels T, Ortiz-Sanchez E, Luria-Perez R, Quintero R, Helguera G, Bonavida B, et al.
J Immunother
. 2011 Jun;
34(6):500-8.
PMID: 21654517
We previously developed an antibody-avidin fusion protein (ch128.1Av) targeting the human transferrin receptor 1 (TfR1, also known as CD71), which demonstrates direct in vitro cytotoxicity against malignant hematopoietic cells. This...
6.
Suzuki E, Daniels T, Helguera G, Penichet M, Umezawa K, Bonavida B
Int J Oncol
. 2010 Apr;
36(5):1299-307.
PMID: 20372806
Multiple myeloma (MM) is an incurable disease of malignant plasma cells. Recent therapeutic advancements have resulted in improved response rates, however, there is no improvement in overall survival, therefore, new...
7.
Mediavilla-Varela M, Pacheco F, Almaguel F, Perez J, Sahakian E, Daniels T, et al.
Mol Cancer
. 2009 Sep;
8:68.
PMID: 19715609
Background: Hormone-refractory prostate cancer (HRPC) is characterized by poor response to chemotherapy and high mortality, particularly among African American men when compared to other racial/ethnic groups. It is generally accepted...
8.
Morizono K, Xie Y, Helguera G, Daniels T, Lane T, Penichet M, et al.
J Gene Med
. 2009 May;
11(8):655-63.
PMID: 19455593
Background: Targeted gene transduction in vivo is the ultimate preferred method for gene delivery. We previously developed targeting lentiviral vectors that specifically recognize cell surface molecules with conjugated antibodies and...
9.
Karagiannis P, Singer J, Hunt J, Gan S, Rudman S, Mechtcheriakova D, et al.
Cancer Immunol Immunother
. 2008 Oct;
58(6):915-30.
PMID: 18941743
Trastuzumab (Herceptin), a humanized IgG1 antibody raised against the human epidermal growth factor receptor 2 (HER2/neu), is the main antibody in clinical use against breast cancer. Pre-clinical evidence and clinical...
10.
Baritaki S, Suzuki E, Umezawa K, Spandidos D, Berenson J, Daniels T, et al.
J Immunol
. 2008 Apr;
180(9):6199-210.
PMID: 18424742
TRAIL promotes apoptotic tumor cell death; however, TRAIL-resistant tumors need to be sensitized to reverse resistance. Proteasome inhibitors potentiate TRAIL apoptosis in vitro and in vivo and correlate with up-regulation...